What Do Australian Clinical Labs'(ASX:ACL) FY26 Results Reveal About the Pathology Sector?

Sonal Goyal

05 November 2026 06:16 PM AEDT

What Do Australian Clinical Labs'(ASX:ACL) FY26 Results Reveal About the Pathology Sector?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• FY26 Revenue came in at A$735.8 million, down 0.7% year-over-year on a statutory basis

• Underlying Earnings Per Share rose 8.5% to 18.33 cents, while statutory EPS declined 24.1% to 12.36 cents

• A fully franked final Dividend of 9.25 cents per share was declared, with a Record Date of 3 September 2026

Australian Clinical Labs(ASX:ACL) closed at A$3.20 on 05 November 2026, edging up 0.95% during the session. The S&P/ASX 200 (XJO) gained 2.61%, adding 230.60 points to settle at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) rose 3.64%, gaining 1,240.30 points to reach 35,329.10. Overnight gains on Wall Street, driven by Democrats' decisive victory in the U.S. midterm elections, provided a tailwind for global Equity markets. Australian Clinical Labs is one of Australia's leading private pathology services providers, operating laboratories and collection centres across all states and territories except Tasmania.

FY26 Financial Performance

On 17 August 2026, Australian Clinical Labs released its FY26 results for the year ended 30 June 2026. Total revenue from ordinary activities came in at A$735.8 million, a marginal decline of 0.7% compared with the prior year. On an underlying basis, which excludes non-recurring items, profit attributable to members increased 4.6% to A$35.2 million. Statutory profit, however, fell 26.9% to A$23.7 million.

Underlying Basic Earnings Per Share rose 8.5% to 18.33 cents, while underlying diluted EPS increased 8.8% to 18.28 cents. On a statutory basis, basic EPS declined 24.1% to 12.36 cents. Net tangible assets per ordinary security moved to negative A$0.08 from positive A$0.03 in the prior year, while net asset backing stood at A$0.80 per share, down from A$0.88.

Dividend and Capital Returns

The Board declared a fully franked final dividend of 9.25 cents per share, up from 9.00 cents in FY25. Combined with the Interim Dividend of 3.75 cents per share, total FY26 dividends amounted to 13.00 cents per share. The record date was set for 3 September 2026 with payment on 23 September 2026. The Dividend reinvestment plan remained suspended for the final dividend.

About Australian Clinical Labs

Australian Clinical Labs is a leading private provider of pathology services in Australia. The company operates laboratories and pathology collection centres in all Australian states and territories with the exception of Tasmania. ACL is one of the largest private hospital pathology businesses nationally, providing a range of diagnostic testing services to healthcare providers and patients. The company listed on the ASX in 2021 following its demerger from Healthscope.

Sector Context

The Australian pathology sector saw a return to normalised testing volumes in FY26 as COVID-related testing continued to decline. The broader ASX healthcare sector advanced during the 05 November session, with the Health Care sub-index outperforming the market. Pathology operators face an environment of ongoing government funding reviews and competitive pressures, while demographic trends including an ageing population continue to underpin long-term Demand for diagnostic services.

Risks

Key risks include potential changes to Medicare rebate structures and government healthcare funding that could affect revenue per test. Competitive pressures from other major pathology operators and new market entrants remain relevant. Labour cost Inflation and recruitment challenges across the healthcare sector may also affect margins. The gap between statutory and underlying earnings highlights non-recurring items that may recur in different forms.

Catalysts on Watch

The progression of underlying earnings growth and the trajectory of the dividend payout will be monitored by the market. Any developments regarding industry consolidation or Acquisition activity in the pathology sector could also be material. The company's ability to maintain or grow its share of the private hospital pathology market and expand its collection centre network represent additional catalysts.

Looking Ahead

Australian Clinical Labs delivered a mixed FY26 outcome, with underlying earnings growth contrasting with statutory profit declines. The increased dividend signals the Board's confidence in the company's cash generation, while the pathology sector's fundamentals continue to be supported by Australia's ageing population and increasing demand for diagnostic services.

FAQs

Q: What was Australian Clinical Labs' FY26 revenue?

A: FY26 revenue was A$735.8 million, a decline of 0.7% compared with the prior year.

Q: How did ACL's underlying earnings per share perform in FY26?

A: Underlying basic EPS rose 8.5% to 18.33 cents per share, while statutory basic EPS fell 24.1% to 12.36 cents.

Q: What dividend did ACL declare for FY26?

A: ACL declared a fully franked final dividend of 9.25 cents per share, bringing total FY26 dividends to 13.00 cents per share.

Q: Where does Australian Clinical Labs operate?

A: ACL operates laboratories and pathology collection centres in all Australian states and territories except Tasmania.

Q: When was the FY26 final dividend record date?

A: The record date was 3 September 2026, with payment on 23 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.